Agios Pharmaceuticals, Inc. (AGIO) stock
AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302% below fair value
$31.59−0.17 (-0.54%)
Close on Nov 13, 2026Market cap $1.89BP/E –Yield –
Agios Pharmaceuticals enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Agios Pharmaceuticals's enterprise value was $956.23M on Nov 11, 2026, against $401.77M a year earlier. Over the last 5 years it ranged from -$133.50M to $1.97B, with a median of $525.31M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $956.23M | +233.9% |
| 2025 | Dec 31, 2025 | $286.38M | +64.8% |
| 2024 | Dec 31, 2024 | $173.73M | -53.3% |
| 2023 | Dec 29, 2023 | $372.14M | -31.3% |
| 2022 | Dec 30, 2022 | $541.42M | +35.9% |
| 2021 | Dec 31, 2021 | $398.49M | -82.5% |
| 2020 | Dec 31, 2020 | $2.28B | +0.2% |
| 2019 | Dec 31, 2019 | $2.27B | +25.9% |
| 2018 | Dec 31, 2018 | $1.80B | -31.9% |
| 2017 | Dec 29, 2017 | $2.65B | +125.4% |
| 2016 | Dec 30, 2016 | $1.17B | -43.8% |
| 2015 | Dec 31, 2015 | $2.09B | -42.9% |
| 2014 | Dec 31, 2014 | $3.66B | +473.7% |
| 2013 | Dec 31, 2013 | $638.22M | – |
See a number that looks wrong?